17,261 trials
Metastatic Prostate Adenocarcinoma
Primary: Evaluate Equivalence Between 68GA-PSMA-cyclotron and 68Ga-PSMA-generator Across Varying Pathologic Lesions — 0.98; 0.98; 0.99; 0.99 ICC estimate
Amyloidosis · Plasma Cell Myeloma
Primary: Maximum Tolerated (MTD) Dose of Cyclophosphamide With Ixazomib and Dexamethasone (Phase I) — 4; 40 mg weekly
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Primary: Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen — 0; 1; 0 Participants
Abdominoplasty
Primary: Mean (Peak) Plasma Concentration (Cmax) — 0; 573 ng/mL
Breast Cancer
Primary: Number of Participants That Achieved Pathologic Complete Response (CR) — 11 Participants
Squamous Cell Carcinoma · Head and Neck Cancer
Primary: Toxicity Rate — 20 Number of adverse events
Adult Lymphoblastic Lymphoma
Primary: Percentage of Subjects Disease-free Survival — 63.2 percentage of participants
Sarcoma
Primary: Phase I: Recommended Phase II Dose of Vorinostat — 300 mg/day of Vorinostat
Alcohol Use Disorder
Primary: Craving to Drink — 33.84; 28.31 score on a scale — p=0.36
Multiple Sclerosis
Primary: Symbol Digit Modalities Test (SDMT) — 36.9; 46.8 score on a scale
COVID-19
Primary: Time to Sustained Recovery Through Day 29 — 12.00; 13.00; 13.00 days — p=0.7273
Rosacea
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 5; 6 Participants
Neurogenic Orthostatic Hypotension
Primary: Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score — 4.61; 4.17; 3.35; 3.5 Score on a scale
Fibromyalgia
Primary: Mean (SD) Glx/Total Creatine Levels in Dorsal Anterior Cingulate Cortex (dACC): NYX-2925 20 mg and 200 mg PO QD at Week 4 and Week 6, Respectively. — 2.1670; 2.0550…
Prostatic Neoplasms · Neoplasms of Prostate · Prostate Cancer
Primary: Number of Grade 3 Adverse Events (AEs) Probably Related to the Vaccine Treatment — 1 Adverse events